ABSTRACT
Purpose Thorough investigation of sudden cardiac death (SCD) in those aged 1-40 years commonly reveals a heritable cause, yet access to postmortem genetic testing is variable. We explore practices of postmortem genetic testing and attitudes of healthcare professionals worldwide.
Methods A survey was administered among healthcare professionals recruited through professional associations, social media and networks of researchers. Topics included practices around postmortem genetic testing, level of confidence in healthcare professionals’ ability, and attitudes towards postmortem genetic testing practices.
Results There were 112 respondents, with 93% from North America, Europe and Australia and 7% from South America, Asia and Africa. Only 30% reported autopsy as mandatory, and overall practices were largely case-by-case and not standardised. North American respondents (87%) more often perceived practices as ineffective compared to those from Europe (58%) and Australia/New Zealand (48%, p=0.002). Where a heritable cause is suspected, 69% considered postmortem genetic testing and 61% offered genetic counseling to surviving family members; financial resources varied widely. Half believed practices in their countries perpetuated health inequalities.
Conclusion Postmortem genetic testing is not consistently available in the investigation of young SCD despite being a recommendation in international guidelines. Access to postmortem genetic testing, guided by well-resourced multidisciplinary teams, is critical in ascertaining a cause of death in many cases.
Competing Interest Statement
L.M. van den Heuvel: No disclosures J. Do: No disclosures L. Yeates: No disclosures H. MacLeod: No disclosures C.A. James: Research grant support from Boston Scientific Corp. J. Duflou: No disclosures J.R. Skinner: No disclosures C. Semsarian: No disclosures J.P. van Tintelen: No disclosures J. Ingles: Research grant support from Myokardia, Inc.
Funding Statement
This work was supported by the Netherlands Cardiovascular Research Initiative, an initiative with support of the Dutch Heart Foundation (2015-12 eDETECT) and the eDETECT Young Talent Fund (LvdH). LY is a recipient of a co-funded National Heart Foundation of Australia/ National Health and Medical Research Council (NHMRC) PhD scholarship (#102568/ #191351). CS is the recipient of a NHMRC Practitioner Fellowship (#1154992). JI is the recipient of an NHMRC Career Development Fellowship (#1162929).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethical approval of the local institutional ethics committee was obtained (Sydney Local Health District, RPAH Zone). This study was conducted in accordance to the principles of the Declaration of Helsinki. Completion of the survey was deemed as informed consent given. Individual-level data was de-identified.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Data will be made available upon reasonable request to the corresponding author.
